Cargando…

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

BACKGROUND AND OBJECTIVE: Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with either renal impairment or hepatic impairment, but the impact of both path...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercier, Anne-Kristina, Sunnåker, Mikael, Ueckert, Sebastian, Pawlik, Tadeusz, Henricson, Emilia, Molodetskyi, Oleksandr, Law, Gordon C., Parker, Victoria E. R., Oscarsson, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684621/ https://www.ncbi.nlm.nih.gov/pubmed/37801266 http://dx.doi.org/10.1007/s40262-023-01306-7

Ejemplares similares

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion
por: Palmer, Jennifer C., et al.
Publicado: (2020)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial
por: Stern, Edward P., et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
por: Guthrie, Heather, et al.
Publicado: (2020)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Concurrent validity of the Fitbit for assessing sedentary behavior and moderate-to-vigorous physical activity
por: Redenius, Nicklaus, et al.
Publicado: (2019)

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia
por: Brown, David, et al.
Publicado: (2017)

Comparative studies on tolerance of rice genotypes differing in their tolerance to moderate salt stress
por: Li, Qian, et al.
Publicado: (2017)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD
por: Al-shair, Khaled, et al.
Publicado: (2016)

Personality traits and behaviour biases: the moderating role of risk-tolerance
por: Singh, Yogita, et al.
Publicado: (2022)

A method for zooming of nonlinear models of biochemical systems
por: Sunnåker, Mikael, et al.
Publicado: (2011)

Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine
por: Savi, Lidia, et al.
Publicado: (2014)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022)

Feelings of Parental Authenticity Moderate Concurrent Links Between Breastfeeding Experience and Symptoms of Postpartum Depression
por: Hammond, Mikayela, et al.
Publicado: (2021)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia
por: Hannestad, Jonas, et al.
Publicado: (2020)

Remodeling in the AV block dog is essential for tolerating moderate treadmill activity()
por: van Bavel, Joanne J.A., et al.
Publicado: (2023)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Age and Perceived Employability as Moderators of Job Insecurity and Job Satisfaction: A Moderated Moderation Model
por: Yeves, Jesus, et al.
Publicado: (2019)

Evidence for the embodiment of space perception: concurrent hand but not arm action moderates reachability and egocentric distance perception
por: Grade, Stéphane, et al.
Publicado: (2015)

Influence of MLC901 Alone and with Moderate Exercise on Pain Response Concurrent Due to Stress of Male Mice
por: Nasehi, Maryam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6d1arstru40uvlo8u0p5phr2vu